Leveljump Healthcare (TSXV:JUMP) Research & Development: C$0.00 Mil (TTM As of Sep. 2025)


What is Leveljump Healthcare Research & Development?

Leveljump Healthcare TSXV:JUMP Research & Development is C$0.00 Mil as of Sep. 2025. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Leveljump Healthcare's Research & Development for the three months ended in Sep. 2025 was C$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 was C$0.00 Mil.

Leveljump Healthcare  (TSXV:JUMP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Leveljump Healthcare Research & Development Related Terms

Leveljump Healthcare Research & Development Historical Data

* Premium members only.

The historical data trend for Leveljump Healthcare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Leveljump Healthcare Research & Development Chart

Leveljump Healthcare Annual Data
Trend Aug19 Aug20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Leveljump Healthcare Quarterly Data
Nov20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Leveljump Healthcare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of C$0.00 Mil mean?
Leveljump Healthcare (TSXV:JUMP) has a Research & Development of C$0.00 Mil as of Sep. 2025. Research and development expense is the total cost for research and development activities. View historical data on Leveljump Healthcare and its competitors.
Is Leveljump Healthcare's Research & Development too high?
Leveljump Healthcare's current Research & Development is C$0.00 Mil.
How does Leveljump Healthcare's Research & Development compare to TMO and DHR?
Leveljump Healthcare's Research & Development of C$0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Leveljump Healthcare and its competitors. Leveljump Healthcare's current Research & Development is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Leveljump Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Leveljump Healthcare (TSXV:JUMP) is currently considered Modestly Undervalued. The stock's GF Value™ is C$0.07, compared to a current price of C$0.06 — trading 21.4% below its estimated fair value. The current Research & Development is C$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Leveljump Healthcare (TSXV:JUMP), the current Research & Development is C$0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Leveljump Healthcare Business Description

Address 52 Scarsdale Road, Suite 207, Toronto, ON, CAN, M3B 2R7
Leveljump Healthcare Corp is engaged in providing radiology services both by providing direct patient images and by providing Teleradiology services, which is the process of providing remote off-site reading of radiology scans such as CT, MRI, and X-ray. Its teleradiology services allow hospital staff to scan their emergency room patients, then page the company's radiologist on call, who can then remotely view, via a secured server, the images and diagnose the patient, and provide a report back to the hospital. Leveljump provides its direct-to-patient services at its Independent Healthcare Facilities (IHFs). The company operates as a single segment, with all of its core assets, intellectual property, and development work being conducted in Canada.